-
Roivant Doses First Patient in Gimsilumab Trial for COVID-19 Acute Respiratory Distress Syndrome Prevention
americanpharmaceuticalreview
April 17, 2020
Roivant Sciences announced the first patient was dosed at Temple University Hospital in Philadelphia in an adaptive, randomized, double-blind, placebo-controlled ...
-
Roivant Doses First Patient in Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of Acute Respiratory Distress Syndrome
prnewswire
April 16, 2020
Roivant Sciences announced that the first patient was dosed at Temple University Hospital in Philadelphia in an adaptive, randomized, double-blind, placebo-controlled ...
-
Roivant Develops Gimsilumab for ARDS Associated with COVID-19
americanpharmaceuticalreview
March 23, 2020
Roivant Sciences has engaged with regulators in the United States, Europe, and Asia to rapidly advance the clinical development of gimsilumab for the treatment ...
-
Roivant, Mateon to develop Covid-19 drug candidates
pharmaceutical-technology
March 20, 2020
Roivant Sciences is in discussion with the US, Europe and Asian regulators to develop gimsilumab for treating acute respiratory distress syndrome (ARDS) caused by Covid-19.
-
Sumitomo Dainippon inks strategic collaboration with Roivant Sciences
biospectrumasia
September 06, 2019
To create broad strategic alliance to deliver promising new medicines to patients
-
Roivant Sciences in mega $1.1B raise, looks to add to the family
fiercebiotech
August 10, 2017
The company is looking within and outside the biopharma world with its massive cash hoard